Provided by Tiger Trade Technology Pte. Ltd.

BioVie Inc

1.25
-0.0100-0.79%
Volume:71.80K
Turnover:88.10K
Market Cap:9.35M
PE:-0.24
High:1.26
Open:1.26
Low:1.20
Close:1.26
52wk High:14.60
52wk Low:1.06
Shares:7.48M
Float Shares:7.44M
Volume Ratio:0.45
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.1345
EPS(LYR):-12.1239
ROE:-80.74%
ROA:-47.20%
PB:0.49
PE(LYR):-0.10

Loading ...

BioVie to Host Live Investor Webinar and Q&A Session with CEO Cuong Do

Reuters
·
Yesterday

Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4

GlobeNewswire
·
Yesterday

BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting

GlobeNewswire
·
Feb 12

BRIEF-Option Therapeutics Files For IPO Of 2.3 Million Shares Of Common Stock - SEC Filing

Reuters
·
Jan 26

Option Therapeutics Inc Says Thinkequity Is the Underwriter to IPO

THOMSON REUTERS
·
Jan 26

BioVie Inc. unveils new data on bezisterim's potential in Parkinson's and Alzheimer's therapies

Reuters
·
Jan 11

BioVie Completes Enrollment for Phase 2 SUNRISE-PD Trial Testing Bezisterim in Early Parkinson’s Disease

Reuters
·
Jan 08

BioVie Inc - Topline Results From Sunrise-Pd Trial Expected in 1H 2026

THOMSON REUTERS
·
Jan 08

BioVie Completes Enrollment in Phase 2 Sunrise-Pd Trial in Early Parkinson’s Disease

THOMSON REUTERS
·
Jan 08

Halozyme Therapeutics Elects Jim Lang to Board of Directors

Reuters
·
Dec 09, 2025

Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9

GlobeNewswire
·
Nov 19, 2025

BioVie Inc. Files Initial Statement of Beneficial Ownership for Director Kameel D. Farag

Reuters
·
Oct 28, 2025

BioVie Inc. Files Initial Beneficial Ownership Statement for Director Amy Suzon Chappell

Reuters
·
Oct 28, 2025

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

GlobeNewswire
·
Sep 26, 2025

BioVie Inc. Announces Date for Upcoming Virtual Annual Stockholders Meeting

Reuters
·
Sep 26, 2025